Lorcaserine in combination with XR-Naltrexone for relapse prevention opioid use disorder
Medication trial for the treatment of opiate use disorder
Sponsor: NIDA
Enrolling: Male and Female Patients
Study Length: 8 Weeks
Clinic Visits: 20
IRB Number: 7501
U.S. Govt. ID: NCT03169816
Contact: Daniel Brooks: 212-923-3031 / daniel.brooks@nyspi.columbia.edu
Additional Study Information: This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
This study is closed
Investigator
Frances Levin, MD
Do You Qualify?
Have you been using opiates or heroin for at least 6 months? Yes No
Are you seeking to stop using opiates or heroin? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Daniel Brooks
daniel.brooks@nyspi.columbia.edu
212-923-3031
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE